183 related articles for article (PubMed ID: 17038352)
21. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
[TBL] [Abstract][Full Text] [Related]
22. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
23. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
Scallon B; McCarthy S; Radewonuk J; Cai A; Naso M; Raju TS; Capocasale R
Int Immunopharmacol; 2007 Jun; 7(6):761-72. PubMed ID: 17466910
[TBL] [Abstract][Full Text] [Related]
24. [Potelligent antibodies as next generation therapeutic antibodies].
Shitara K
Yakugaku Zasshi; 2009 Jan; 129(1):3-9. PubMed ID: 19122430
[TBL] [Abstract][Full Text] [Related]
25. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454
[TBL] [Abstract][Full Text] [Related]
26. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
27. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
28. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
Okazaki A; Shoji-Hosaka E; Nakamura K; Wakitani M; Uchida K; Kakita S; Tsumoto K; Kumagai I; Shitara K
J Mol Biol; 2004 Mar; 336(5):1239-49. PubMed ID: 15037082
[TBL] [Abstract][Full Text] [Related]
29. Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells.
Lee JH; Yeo J; Park HS; Sung G; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Protein Expr Purif; 2013 Jan; 87(1):17-26. PubMed ID: 23009882
[TBL] [Abstract][Full Text] [Related]
30. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
32. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
[TBL] [Abstract][Full Text] [Related]
33. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
34. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
[TBL] [Abstract][Full Text] [Related]
35. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
36. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
38. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
[TBL] [Abstract][Full Text] [Related]
39. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies.
Chan KF; Shahreel W; Wan C; Teo G; Hayati N; Tay SJ; Tong WH; Yang Y; Rudd PM; Zhang P; Song Z
Biotechnol J; 2016 Mar; 11(3):399-414. PubMed ID: 26471004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
